Physicians Tweeting About Drugs May Have Conflict of Interest

This article originally appeared here.
Share this content:
Physicians Tweeting About Drugs May Have Conflict of Interest
Physicians Tweeting About Drugs May Have Conflict of Interest

FRIDAY, Sept. 15, 2017 (HealthDay News) -- Most physicians on Twitter with a financial conflict of interest (FCOI) and frequent tweets mention specific drugs for which they have a conflict, according to a study published in the September issue of The Lancet Haematology.

Victoria Kaestner, from the Oregon Health & Science University in Portland, and colleagues examined whether conflicted physicians tweet about specific products for which they have a FCOI. A total of 156 physicians who tweeted a median of 584 times were included, with a 2014 median general payment totaling $13,600.

The researchers found that 81 percent of the physicians mentioned at least one drug from a company for which they had a FCOI and 88 percent mentioned at least one drug for which they did not have an FCOI. Fifty-two percent of the 4,358 total drug mentions regarded conflicted drugs. Only 1.3 percent of the physicians included a disclosure relating to their payment; these were in their twitter biography. Conflicted tweets were more likely to be positive, similarly likely to be neutral, and less likely to be negative, compared with tweets about non-conflicted drugs coded at random.

"Our results raise the concern that financial conflict of interest must be considered with the growing use of social media to discuss cancer products and practices, as well as policies regarding disclosure, divesture, audit, and recusal may be considered," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »